Pacira BioSciences (PCRX) Payables (2010 - 2026)

Pacira BioSciences' Payables history runs 17 years deep, the most recent figure standing at $14.0 million for Q1 2026.

• On a quarterly basis, Payables fell 39.53% year-over-year to $14.0 million in Q1 2026; TTM through Mar 2026 was $14.0 million, a 39.53% decrease from a year earlier, with the FY2025 full-year figure at $15.2 million, down 20.82% from the prior year.
• Payables declined to $14.0 million in Q1 2026 per PCRX's latest filing, from $15.2 million in the prior quarter.
• Across five years, Payables topped out at $30.1 million in Q2 2025 and bottomed at $9.0 million in Q1 2024.
• The 5-year median for Payables is $16.5 million (2023), against an average of $17.5 million.
• Across the five-year window, Payables slumped 47.96% in 2024 and jumped 157.98% in 2025, its largest moves.
• Year by year, Payables stood at $15.2 million in 2022, then advanced by 3.14% to $15.7 million in 2023, then climbed by 21.88% to $19.1 million in 2024, then slipped by 20.82% to $15.2 million in 2025, then slipped by 7.51% to $14.0 million in 2026.
• Per Business Quant, the three latest PCRX Payables figures stand at $14.0 million (Q1 2026), $15.2 million (Q4 2025), and $17.7 million (Q3 2025).